Alere Inc (ALR)

ALR on New York Consolidated

26.30USD
17 May 2013
Price Change (% chg)

$0.11 (+0.42%)
Prev Close
$26.19
Open
$26.28
Day's High
$26.56
Day's Low
$26.01
Volume
560,180
Avg. Vol
670,975
52-wk High
$29.57
52-wk Low
$17.13

ALR

Chart for ALR

About

Alere Inc. is engaged in developing capabilities in near-patient diagnosis, monitoring and health management. The Company’s products and services, as well as its new product development efforts, focuses on cardiology, infectious disease, toxicology, diabetes, oncology and women’s health. The Company operates in three segments:... (more)

Overall

Beta: 1.49
Market Cap (Mil.): $2,137.89
Shares Outstanding (Mil.): 81.29
Dividend: --
Yield (%): --

Financials

  ALR Industry Sector
P/E (TTM): -- 76.95 35.83
EPS (TTM): -1.09 -- --
ROI: -1.24 4.23 18.72
ROE: -5.54 9.06 19.54
Search Stocks

New Issue- Alere sells $450 mln in notes

Nov 29 - Alere Inc on Wednesday sold $450 million of senior notes in the 144a private placement market, said IFR, a Thomson Reuters service. Jefferies, Goldman Sachs and Credit Suisse were the joint bookrunning managers for the sale. BORROWER: ALERE AMT $450 MLN COUPON 7.25 PCT MATURITY 07/01/2018 TYPE SR NTS ISS PRICE 100 FIRST PAY 07/01/2013 MOODY'S B3 YIELD 7.25 PCT SETTLEMENT 12/11/2012 S&P B-MINUS SPREAD N/A PAY FREQ SEMI-

29 Nov 2012

TEXT-S&P Downgrades Alere Inc To 'B', Rates New Notes; Otlk Stbl

-- Alere Inc. is issuing $450 million of unsecured notes, which will, in part, be used to repay the $250 million 7.875% senior notes and $97.5 million outstanding revolver balance.

27 Nov 2012

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Jefferson Research
$20.00
Provider: ValuEngine, Inc.
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks